Ascelia Pharma Provides Orviglance(R) Update Following FDA Type a Meeting

Ascelia Pharma AB (publ) today announces that it has received the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) issued for the Orviglance New Drug Application …